These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9186885)

  • 1. Down-regulation of hepatic lipase expression in experimental nephrotic syndrome.
    Liang K; Vaziri ND
    Kidney Int; 1997 Jun; 51(6):1933-7. PubMed ID: 9186885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome.
    Vaziri ND; Kim CH; Phan D; Kim S; Liang K
    Kidney Int; 2004 Jul; 66(1):262-7. PubMed ID: 15200432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome.
    Vaziri ND; Liang K; Parks JS
    Am J Physiol Renal Physiol; 2001 May; 280(5):F823-8. PubMed ID: 11292624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression of lipoprotein lipase in experimental nephrosis.
    Liang K; Vaziri ND
    J Lab Clin Med; 1997 Oct; 130(4):387-94. PubMed ID: 9358077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND; Liang KH
    Circulation; 2004 Jul; 110(4):419-25. PubMed ID: 15262831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of nitric oxide synthase in nephrotic syndrome: role of proteinuria.
    Ni Z; Vaziri ND
    Biochim Biophys Acta; 2003 Jul; 1638(2):129-37. PubMed ID: 12853118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome.
    Chan MK; Persaud JW; Varghese Z; Moorhead JF
    Aust N Z J Med; 1984 Dec; 14(6):841-7. PubMed ID: 6598053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome.
    Vaziri ND; Liang K
    Kidney Int; 2002 May; 61(5):1769-75. PubMed ID: 11967026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome.
    Liang K; Vaziri ND
    Kidney Int; 1999 Aug; 56(2):621-6. PubMed ID: 10432401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome.
    Kim CH; Kim HJ; Mitsuhashi M; Vaziri ND
    Metabolism; 2007 Oct; 56(10):1377-82. PubMed ID: 17884448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion.
    Shearer GC; Kaysen GA
    Kidney Int; 2006 Aug; 70(4):647-53. PubMed ID: 16807550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.
    Vaziri ND; Gollapudi P; Han S; Farahmand G; Yuan J; Rahimi A; Moradi H
    Nephrol Dial Transplant; 2011 Oct; 26(10):3118-23. PubMed ID: 21459782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of hepatic LDL receptor-related protein in nephrotic syndrome: response to statin therapy.
    Kim S; Kim CH; Vaziri ND
    Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E813-7. PubMed ID: 15585592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
    Vaziri ND
    Kidney Int; 2016 Jul; 90(1):41-52. PubMed ID: 27165836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.
    Liu S; Vaziri ND
    Nephrol Dial Transplant; 2014 Mar; 29(3):538-43. PubMed ID: 24166456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of hepatic LDL receptor expression in experimental nephrosis.
    Vaziri ND; Liang KH
    Kidney Int; 1996 Sep; 50(3):887-93. PubMed ID: 8872963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Interference Targeting Liver Angiopoietin-Like Protein 3 Protects from Nephrotic Syndrome in a Rat Model Via Amelioration of Pathologic Hypertriglyceridemia.
    Zhao Y; Goto M; Vaziri ND; Khazaeli M; Liu H; Farahanchi N; Khanifar E; Farzaneh T; Haslett PA; Moradi H; Soundarapandian MM
    J Pharmacol Exp Ther; 2021 Mar; 376(3):428-435. PubMed ID: 33443084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High density lipoproteinuria in nephrotic syndrome.
    de Mendoza SG; Kashyap ML; Chen CY; Lutmer RF
    Metabolism; 1976 Oct; 25(10):1143-9. PubMed ID: 184367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
    Vaziri ND; Liang K
    Am J Nephrol; 2004; 24(6):606-13. PubMed ID: 15583480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome.
    Shearer GC; Stevenson FT; Atkinson DN; Jones H; Staprans I; Kaysen GA
    Kidney Int; 2001 Jan; 59(1):179-89. PubMed ID: 11135070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.